OÄ Dr. Karin Jutz
Medical fields
General medicine
Gynecology and obstetrics
General medicine
Gynecology and obstetrics
Specialisation
- Breast Health, Breast Cancer
- Menopausal Medicine
Doctor's office
Mobile: +43 699 10 89 40 90
Curriculum Vitae
Education
2003 - 2005 Master of Public Health Graduate Program, Harvard University School of Public Health, Harvard University, Boston, MA, USA
1984 – 1990 Medical School, University of Innsbruck, Innsbruck, Austria
1976 – 1984 High School, Bundesrealgymnasium Reutte, Austria. Degree awarded with honors
Professional Experience
2011 - Full Professor of Clinical-Translational Gynecological Oncology, Vienna University Medical School, Vienna, Austria
2009 - Head of Senology, Department of OB/GYN, Vienna University Medical School, Vienna, Austria
2007 –2009 Deputy Head, Division of Special Gynecology, Department of OB/GYN, Vienna University Medical School, Vienna, Austria
2006 - 2007 Senior Clinical Specialist and Deputy Medical Director, Prince Court Medical Centre, Kuala Lumpur, Malaysia
2002 - Founder and CEO, Hellmann & Moedlinger Ltd, Public Health Consulting
2000 - Expert Evaluator, European Commission, Brussels, Belgium
2003 - 2011 Associate Professor of Obstetrics and Medical Gynecology, Division of Special Gynecology, Medical University of Vienna, Austria
1997 - 2003 Assistant, Department of Special Gynaecology, Vienna University Medical School, Vienna, Austria
1995 – 1997 Postdoctoral Fellow, DeDuve International Institute for Cellular Pathology (ICP), Université Catholique de Louvain, Brussels, Belgium
1994 – 1995 Residency, Department of OB/GYN, Klinikum rechts der Isar - Technical University Hospital, Munich, Germany
1991 – 1993 Postdoctoral Fellow, Lombardi Cancer Research Center, Georgetown University, Washington, DC, USA
Additional training
2001 Johnson & Johnson European Healthcare Leadership Programme, INSEAD, Fontainebleau, France
1998 - Graduate courses in Law, Vienna University, Faculty of Law, Vienna, Austria
1992 Graduate courses in Molecular Biology, Georgetown University, Washington, DC, USA
1988 Advanced Studies Program in Clinical Pharmacology, Department of Medical Pharmacology, Innsbruck University Medical School, Innsbruck, Austria
Licenses and certifications
2006 Clinical Trial Investigator Certificate, Austrian Medical Association, Vienna, Austria
2004 OB/GYN License, Austrian Medical Association, Vienna, Austria
1996 USMLE Certificate, Educational Commission for Foreign Medical Graduates (ECFMG), USA
1995 Medical License, German Medical Association, Munich, Germany
Fellowships and awards
2007 Researcher of the Month, Medical University of Vienna, Vienna, Austria
2004 Award of the Austrian Society for Senology´, Austrian Society for Senology, Vienna, Austria
2003 Forschungspreis des Fonds der Stadt Wien für innovative interdisziplinäre Krebsforschung, Viennna, Austria
2003 Research Fellowship, Menachem-Elias Foundation, Vienna Austria
1999 Research Award of the `Erste Bank der österreichischen Sparkassen AG´, Erste Bank, Vienna, Austria
1999 `Hugo Husslein Award´, Austrian Society for Obstetrics and Gynecology, Vienna, Austria
1999 `Hans und Blanka Moser-Award´, Hans und Blanka Moser-Foundation, Vienna, Austria
1999 `Schönmann-Cancer Research Award´, Schönmann Foundation, Vienna, Austria
1998 `Theodor-Körner-Award`, Theodor-Körner Foundation, Vienna, Austria
1998 Award of the Austrian Society for Senology´, Austrian Society for Senology, Vienna, Austria
1998 `HOECHST-Award´, Hoechst Austria AG, Vienna, Austria
1996 `Haas-Teichen Fellowship`, DeDuve International Institute for Cellular Pathology, Brussels, Belgium
1995 `ICP Fellowship´ - International Institute for Cellular and Molecular Pathology, Brussels, Belgium
1993 `Eduard Wallnöfer Award´ - State Council of the Tyrol, Innsbruck, Austria
1991 `Auslandsstipendium zur Förderung wissenschaftlicher Arbeiten´ Scholarship - Austrian Federal Department of Science and Research, Vienna, Austria
1986 `Young Researcher Award´ - Philips Industries and Austrian Federal Department of Schience and Research, Vienna, Austria
Professional memberships
Member of the Board, Austrian Society of Obstetrics and Gynecology (OEGGG)
Member of the Board, Austrian Society of Senology (OGS)
Member of the Board, Austrian Society for Gynecological Oncology (AGO)
Member, American Society of Clinical Oncology (ASCO)
Member, American Association for Cancer Research (AACR)
Member, Austrian Society for Public Health (APH)
Member, Harvard University Alumni Association
Publications
Books and Bookchapters
Singer CF (2009) Ethik und medizinisches Screening (Fischer M and Hengstschläger M ed), Peter Lang, Internationaler Verlag der Wissenschaften, in preparation
Singer CF (2009) Prognosefaktoren und prädiktive Faktoren beim Mammakarzinom: vom Hormonrezeptor zum Gen Chip, in Strahlentherapie und Onkologie 2009/2010. ISBN 978-3-940671-16-5 Düsseldorf University Press
Kubista E, Singer CF (2009) Zielgerichtete Therapien zur Therapie des Mammakarzinoms. Uni-Med Verlag Publishers, Bremen, in preparation
Singer CF (2009) Epidemiologie des Mammakarzinoms. Manual der Gynäkologischen Onkologie (A Reinthaller, L Hefler, ed.) ISBN 978-3-9501446-1-1, MedMedia Verlag, Vienna
Menzel CR, Singer CF, (2009) Brustaufbau. Manual der Gynäkologischen Onkologie (A Reinthaller, L Hefler, ed.) ISBN 978-3-9501446-1-1, MedMedia Verlag, Vienna
Kubista E, Singer CF, Seifert M (2008) Aromatasehemmer in der endokrinen Therapie des Mammakarzinoms ISBN 978—89599-280-3, Uni-Med Verlag Publishers, Bremen
Singer CF, Gschwantler-Kaulich D, Fink-Retter A, Kubista E, Czerwenka K and Hudelist G (2006) Significance and Prognostic Value of Estradiol Modulating Enzymes in Breast Cancer. New Research Communications of Tumor Markers (F. Columbus, ed.) Nova Science Publishers, in press
Hudelist G, Czerwenka K, Kubista E, Wieser F, Tschugguel W, and Singer CF (2005) Interleukin-1 System and Sex Steroid Receptor Gene Expression In Human Endometrial Cancer. Ovarian Cancer, New Research (A.P. Bardos, ed.) ISBN 1594542414, Nova Science Publishers
Singer CF, Rasmussen A, Lippman ME, and Cullen KJ (1999) Breast cancer cells influence the pattern of cytokine expression in neighbouring breast fibroblasts via paracrine interactions. Proc. 11th Int. Meeting of the Eur. Soc. Of Gyn. Onc. (Bosze, Maggino, De Oliveira et Onnis, ed.) Monduzzi Editore, 3-7
Kokorine I, Nisolle M, Donnez J, Singer CF, Galant C, Eeckhout Y, Courtoy PJ, and Marbaix E (1999) Matrix Metalloproteinases and endometriosis. Understanding Endometriosis: Proc. VIth Int. World Congr. on Endometriosis, (A. Lemay, ed.) Parthenon Publ. Press, 239-250
Singer C (1987) `Der Plansee - History and Scenary of an Austrian Lake`, ISBN 3-85423-074-5, Steiger Publishing Company, Innsbruck, Austria
Scientific Papers
Antoniou AC, Sinilnikova OM, McGuffog L, Healey S, Nevanlinna H, Heikkinen T, Simard J, Spurdle AB, Beesley J, Chen X; Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer, Neuhausen SL, Ding YC, Couch FJ, Wang X, Fredericksen Z, Peterlongo P, Peissel B, Bonanni B, Viel A, Bernard L, Radice P, Szabo CI, Foretova L, Zikan M, Claes K, Greene MH, Mai PL, Rennert G, Lejbkowicz F, Andrulis IL, Ozcelik H, Glendon G; OCGN, Gerdes AM, Thomassen M, Sunde L, Caligo MA, Laitman Y, Kontorovich T, Cohen S, Kaufman B, Dagan E, Baruch RG, Friedman E, Harbst K, Barbany-Bustinza G, Rantala J, Ehrencrona H, Karlsson P, Domchek SM, Nathanson KL, Osorio A, Blanco I, Lasa A, Benítez J, Hamann U, Hogervorst FB, Rookus MA, Collee JM, Devilee P, Ligtenberg MJ, van der Luijt RB, Aalfs CM, Waisfisz Q, Wijnen J, van Roozendaal CE; HEBON, Peock S, Cook M, Frost D, Oliver C, Platte R, Evans DG, Lalloo F, Eeles R, Izatt L, Davidson R, Chu C, Eccles D, Cole T, Hodgson S; EMBRACE, Godwin AK, Stoppa-Lyonnet D, Buecher B, Léoné M, Bressac-de Paillerets B, Remenieras A, Caron O, Lenoir GM, Sevenet N, Longy M, Ferrer SF, Prieur F; GEMO, Goldgar D, Miron A, John EM, Buys SS, Daly MB, Hopper JL, Terry MB, Yassin Y; Breast Cancer Family Registry, Singer C, Gschwantler-Kaulich D, Staudigl C, Hansen TO, Barkardottir RB, Kirchhoff T, Pal P, Kosarin K, Offit K, Piedmonte M, Rodriguez GC, Wakeley K, Boggess JF, Basil J, Schwartz PE, Blank SV, Toland AE, Montagna M, Casella C, Imyanitov EN, Allavena A, Schmutzler RK, Versmold B, Engel C, Meindl A, Ditsch N, Arnold N, Niederacher D, Deissler H, Fiebig B, Suttner C, Schönbuchner I, Gadzicki D, Caldes T, de la Hoya M, Pooley KA, Easton DF, Chenevix-Trench G; CIMBA. Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum Mol Genet 18(22): 4442-56
IF 7,249
Pfeiler G, Hudelist G, Wülfing P, Mattsson B, Königsberg R, Kubista E, Singer CF. Impact of AdipoR1 expression on breast cancer development (2010) Gynecol Oncol.,Jan 11. [Epub ahead of print]
IF 2,919
Neuhausen SL, Brummel S, Ding YC, Singer CF, Pfeiler G, Lynch HT, Nathanson KL, Rebbeck TR, Garber JE, Couch F, Weitzel J, Narod SA, Ganz PA, Daly MB, Godwin AK, Isaacs C, Olopade OI, Tomlinson G, Rubinstein WS, Tung N, Blum JL, Gillen DL (2009) Genetic variation in insulin-like growth factor signaling genes and breast cancer risk among BRCA1 and BRCA2 carriers. Breast Cancer Res. Oct 20;11(5):R76. [Epub ahead of print]
IF 5,050
Osorio A, Milne RL, Pita G, Peterlongo P, Heikkinen T, Simard J, Chenevix-Trench G, Spurdle AB, Beesley J, Chen X, Healey S; KConFab, Neuhausen SL, Ding YC, Couch FJ, Wang X, Lindor N, Manoukian S, Barile M, Viel A, Tizzoni L, Szabo CI, Foretova L, Zikan M, Claes K, Greene MH, Mai P, Rennert G, Lejbkowicz F, Barnett-Griness O, Andrulis IL, Ozcelik H, Weerasooriya N; OCGN, Gerdes AM, Thomassen M, Cruger DG, Caligo MA, Friedman E, Kaufman B, Laitman Y, Cohen S, Kontorovich T, Gershoni-Baruch R, Dagan E, Jernström H, Askmalm MS, Arver B, Malmer B; SWE-BRCA, Domchek SM, Nathanson KL, Brunet J, Ramón Y Cajal T, Yannoukakos D, Hamann U; HEBON, Hogervorst FB, Verhoef S, Gómez García EB, Wijnen JT, van den Ouweland A; EMBRACE, Easton DF, Peock S, Cook M, Oliver CT, Frost D, Luccarini C, Evans DG, Lalloo F, Eeles R, Pichert G, Cook J, Hodgson S, Morrison PJ, Douglas F, Godwin AK; GEMO, Sinilnikova OM, Barjhoux L, Stoppa-Lyonnet D, Moncoutier V, Giraud S, Cassini C, Olivier-Faivre L, Révillion F, Peyrat JP, Muller D, Fricker JP, Lynch HT, John EM, Buys S, Daly M, Hopper JL, Terry MB, Miron A, Yassin Y, Goldgar D; Breast Cancer Family Registry, Singer CF, Gschwantler-Kaulich D, Pfeiler G, Spiess AC, Hansen TV, Johannsson OT, Kirchhoff T, Offit K, Kosarin K, Piedmonte M, Rodriguez GC, Wakeley K, Boggess JF, Basil J, Schwartz PE, Blank SV, Toland AE, Montagna M, Casella C, Imyanitov EN, Allavena A, Schmutzler RK, Versmold B, Engel C, Meindl A, Ditsch N, Arnold N, Niederacher D, Deissler H, Fiebig B, Varon-Mateeva R, Schaefer D, Froster UG, Caldes T, de la Hoya M, McGuffog L, Antoniou AC, Nevanlinna H, Radice P, Benítez J; CMBA (2009) Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA) Br J Cancer 101(12):2048-54
IF 4,846
Filipits M, Rudas M, Heinzl H, Jakesz R, Kubista E, Lax S, Schippinger W, Dietze O, Greil R, Stiglbauer W, Kwasny W, Nader A, Stierer M, Gnant MF; Austrian Breast and Colorectal Cancer Study Group (Collaborator Singer C);. Low p27 expression predicts early relapse and death in postmenopausal hormone receptor-positive breast cancer patients receiving adjuvant tamoxifen therapy (2009) Clin Cancer Res. 15(18):5888-94
IF 6,488
Fink-Retter A, Czerwenka K, Gschwantler-Kaulich D, Hudelist G, Pischinger K, Manavi M, Kubista E, Singer CF (2009) Proteomics in mammary cancer research. Eur J Gynaecol Oncol. 2009;30(6):635-9.
IF 0,641
Rebbeck TR, Mitra N, Domchek S, Wan F, Chuai S, Friebel T, Panossian S, Spurdle A, Chenevix-Trench G, KConFab, Singer CF, Pfeiler G, Neuhausen S, Lynch H, Garber J, Weitzel J, Isaacs C, Couch F, Narod S, Rubinstein W, Tomlinson G, Ganz P, Olopade O, Tung N, Blum J, Greenberg R, Nathanson K, Daly M (2009) Modification of Ovarian Cancer Risk by BRCA1/2 Interacting Genes in a Multicenter Cohort of BRCA1/2 Mutation Carriers. Cancer Research 69(14): 5801-10
IF 7,672
Grunt TW, Wagner R, Grusch M, Berger W, Singer CF, Marian B, Zielinski CC, Lupu R (2009) Interaction between fatty acid synthase- and ErbB-systems in ovarian cancer cells. Biochemical and Biophysical Research Communications 385(3): 454-9.
IF 2,749
Hudelist G, Oberwinkler KH, Singer CF, Tuttlies F, Rauter G, Ritter O, Keckstein J (2009) Combination of Transvaginal Sonography (TVS) and Clinical Examination (PV) for Preoperative Diagnosis of Pelvic Endometriosis, Hum Repr 24(5): 1018-24
IF 3,543
Johnatty SE, Couch FJ, Fredericksen Z, Tarrell R, Spurdle AB, Beesley J, Chen X; kConFab Investigators; AOCS Group; The Swedish BRCA1 and BRCA2 Study Collaborators, Gschwantler-Kaulich D, Singer CF, Fuerhauser C, Fink-Retter A, Domchek SM, Nathanson KL, Pankratz VS, Lindor NM, Godwin AK, Caligo MA, Hopper J, Southey MC, Giles GG, Justenhoven C, Brauch H, Hamann U, Ko YD, Heikkinen T, Aaltonen K, Aittomäki K, Blomqvist C, Nevanlinna H, Hall P, Czene K, Liu J, Peock S, Cook M, Platte R, Gareth Evans D, Lalloo F, Eeles R, Pichert G, Eccles D, Davidson R, Cole T, Cook J, Douglas F, Chu C, Hodgson S, Paterson J, Hogervorst FB, Rookus MA, Seynaeve C, Wijnen J, Vreeswijk M, Ligtenberg M, van der Luijt RB, van Os TA, Gille HJ, Blok MJ; HEBON, Issacs C, Humphreys MK, McGuffog L, Healey S, Sinilnikova O, Antoniou AC, Easton DF, Chenevix-Trench G; on behalf of the Breast Cancer Association Consortium and the Consortium of Investigators of Modifiers of BRCA1/2. No evidence that GATA3 rs570613 SNP modifies breast cancer risk. Breast Cancer Res Treat. 2008 Dec 11. [Epub ahead of print]
IF: 4,453
Singer CF, Hudelist G, Fuchs E, Köstler W, Fink-Retter A, Gschwantler-Kaulich D, Gnant M, Lamm W, Rudas M, Czerwenka K, Kubista E (2009) Incomplete Surgical Resection of DCIS Results in Activation of HER-2 in Residual Breast Cancer Cells, Endocrine-Related Cancer 16(1): 73-83
IF: 5,193
Kenemans P, Bundred NJ, Foidart JM, Kubista E, von Schoultz B, Sismondi P, Vassilopoulou-Sellin R, Yip CH, Egberts J, Mol-Arts M, Mulder R, van Os S, Beckmann MW, LIBERATE Study Group (Collaborator Singer CF) (2009) Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial, Lancet Oncol 10(2): 135-46
IF 12,247
Singer CF, Gschwantler-Kaulich D, Fink-Retter A, Pfeiler G, Walter, I, Hudelist G, Helmy S, Spiess A, Lamm W, and Kubista E (2008) Lamm, and Ernst Kubista (2009) HER2 overexpression and activation, and tamoxifen efficacy in receptor-positive early breast cancer, J Cancer Res Clin Oncol 135(6): 807-13
IF: 2,366
Hudelist G, Huber A, Auer M, Knöfler M, Saleh L, Hrachowitz C, Huber JC, Kubista E, Manavi M, and Singer CF (2009) Administration of beta-HCG leads to dose-dependent changes of gene expression signature of endometriotic stromal cells. J Cancer Res Clin Oncol, accepted
IF: 2,366
Singer CF (2008) Neoadjuvant endocrine therapy in breast cancer Breast Care 3(5): 303-311
IF: 0,040
Hudelist G, Wuelfing P, Czerwenka K, Knöfler M, Haider S, Fink-Retter A, Gschwantler-Kaulich D, Pfeiler G, Kubista E, Singer CF (2009) Beta-hCG/LH receptor (b-HCG/LH-R) expression is increased in invasive versus preinvasive breast cancer: implications for breast carcinogenesis? J Cancer Res Clin Oncol. 135 (2): 191-195
IF: 2,366
Singer CF (2008) Climacteric complaints after breast cancer - Is HRT an option? Breast Care, 3:204-209
IF: 0,040
Singer CF, Koestler WJ, and Hudelist G (2008) Predicting the efficacy of trastuzumab-based therapy in breast cancer: current standards and future strategies BBA - Reviews on Cancer, 1786(2):105-13
IF: 7,264
Bennink HJTC, Singer C, Simoncini T, Genazzani AR, Holinka CF, Kubista E (2008) Estetrol, a pregnancy-specific human steroid, prevents and suppresses mammary tumor growth in a rat model Climacteric 11(Suppl.1): 29
IF: 2,275
Mlineritsch B, Tausch C, Singer C, Luschin-Ebengreuth G, Jakesz R, Ploner F, Stierer M, Melbinger E, Menzel C, Urbania A, Fridrik M, Steger G, Wohlmuth P, Gnant M, Greil R; on behalf of the Austrian Breast, Colorectal Cancer Study Group (ABCSG). (2008) Exemestane as primary systemic treatment for hormone receptor positive post-menopausal breast cancer patients: a phase II trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-17). Breast Cancer Res Treat 14(6):1767-74
IF: 4,453
Rudas M, Lehnert M, Huynh A, Jakesz R, Singer C, Lax S, Schippinger W, Dietze O, Greil R, Stiglbauer W, Kwasny W, Grill R, Stierer M, Gnant MF, Filipits M; for the Austrian Breast and Colorectal Cancer Study Group (2008) Cyclin D1 Expression in Breast Cancer Patients Receiving Adjuvant Tamoxifen-Based Therapy. Clin Cancer Res 14(6):1767-1774
IF: 6,250
Hudelist G, Huber A, Knoefler M, Haider S, Kolbus A, Czerwenka K, Helmy S, Kubista E, and Singer CF (2008) Beta-hCG/LH receptor (b-HCG/LH-R) expression in eutopic endometrium and endometriotic implants: evidence for b-HCG sensitivity of endometriosis, Repr Sciences, 15(6): 543-51
IF: 2,379
Hudelist G, Wülfing P, Kersting C, Burger H, Mattsson B, Czerwenka K, Kubista E, Gschwantler-Kaulich D, Fink-Retter A, Singer CF (2008) Expression of aromatase and estrogen sulfotransferase in preinvasive and invasive breast cancer. J Cancer Res Clin Oncol 134(1):67-73
IF: 2,366
Hudelist G, Czerwenka K, Keckstein J, Haas C, Fink-Retter A, Gschwantler-Kaulich D, Kubista E, Singer CF (2007) Expression of aromatase and estrogen sulfotransferase (EST) in eutopic and ectopic endometrium - evidence for unbalanced estradiol production in endometriosis Repr Sciences 14(8):798-805
IF: 2,958
Singer CF, Gschwantler-Kaulich D, Fink-Retter A, Haas C, Hudelist G, Czerwenka K, and Kubista E (2008). Differential Gene Expression Profile in Breast Cancer-derived Stromal Fibroblasts, Breast Cancer Res Treat, 110(2):273-81
IF: 4,453
Hudelist G , Wagner T, Rosner M, Fink-Retter A, Gschwantler-Kaulich D, Czerwenka K, Kroiss R, Tea M, Pischinger K, Köstler WJ, Attems J, Mueller R, Blaukopf C, Kubista E, Hengstschläger M and Singer CF (2007) Intratumoral IGF-1 protein expression is selectively up-regulated in breast cancer patients with BRCA1/2 mutations. Endocrine-Related Cancer 14(4): 1053-1062
IF: 4,763
Huber A, Hudelist G, Auer M, Knöfler M, Saleh L, Hrachowitz C, Huber JC, Czerwenka K, Kubista E and Singer CF (2007) Effect of highly purified hCG preparations on the gene expression signature of stromal cells derived from endometriotic lesions: potential mechanisms for the therapeutic effect of beta-HCG in vivo. Fertil Steril 88: 1232-1239
IF: 3,168
Steger GS, Galid A, Gnant M, Mlineritsch B, Lang A, Tausch C, Rudas M, Greil R, Wenzel C, Singer CF, Haid A, Pöstlberger S, Samonigg H, Luschin-Ebengreuth G, Kwasny W, Klug E, Kubista E, Menzel C, and Jakesz R for the Austrian Breast and Colorectal Cancer Study Group (ABCSG) (2007) Pathologic Complete Response with 6 vs 3 Cycles of Neoadjuvant Epirubicin/Docetaxel plus G-CSF in Operable Breast Cancer: Results of ABCSG –14. J Clin Oncol 25 (15): 2012-2018
IF: 15,484
Gschwantler-Kaulich D, Fink-Retter A, Hudelist G, Bachrich T, Ledesma M, Ruecklinger E, Kubista E and Singer CF (2007). Efficacy of primary systemic chemotherapy regimen containing anthracyclines with/without taxanes in comparison to CMF in women with early breast cancer J. Chemother 19(6):731-738
IF: 1,374
Kubista E, Planellas-Gomez JVM, Dowsett M, Foidart JM, Pohlodek K, Serreyn R, Nechushkin M, Manikhas AG, Semiglazov VF, Hageluken CCM, and Singer CF (2007). Effect of Tibolone on Breast Cancer Cell Proliferation in postmenopausal ER+ patients: Results from a double-blind, placebo-controlled, randomized Clinical Trial (STEM). Clin Cancer Res 13 (14): 4185-90
IF: 6,177
Hudelist G, Wülfing P, Kersting C, Burger H, Mattsson B, Czerwenka K, Kubista E, Gschwantler-Kaulich D, Fink-Retter A, Singer CF (2007). Expression of aromatase and estrogen sulfotransferase (EST) in preinvasive and invasive breast cancer. J Cancer Res Clin Oncol 134(1):67-73
IF: 2,366
Reich O, Hudelist G and Singer CF (2006) Estrogen Sulphotransferase Expression in Endometrial Stromal Sarcomas: an Immunohistochemical Study, Pathology - Research and Practice, 203 (2): 85-87
IF: 0,892
Singer CF, Fink-Retter A, Gschwantler-Kaulich D, Thalhammer T, Hudelist G, Mueller R, Czerwenka K and Kubista E (2006) Selective spatial up-regulation of intratumoral stromal aromatase in breast cancer patients: evidence for imbalance of local estrogen metabolism Endocrine-Related Cancer, 13: 1101-1107
IF: 4,905
Fink-Retter A, Gschwantler-Kaulich D, Hudelist G, Mueller R, Kubista E, Czerwenka K and Singer CF (2007) Differential spatial expression and activation pattern of EGFR and HER2 in human breast cancer. Oncology Reports, 18 (2): 299-304
IF: 1,567
Singer CF, Hudelist G, Gschwantler-Kaulich D, Fink-Retter A, Mueller R, Walter I, Czerwenka K and Kubista E (2006) Interleukin-1 alpha protein secretion in breast cancer is associated with poor differentiation and estrogen receptor alpha negativity Int J Gynecol Cancer 16, Suppl 2: 556-559
IF: 1,147
Hudelist G, Singer CF, Pischinger K, Kaserer K, Manavi M, Kubista E, Czerwenka K (2006) Proteomic Analysis in Human Breast Cancer: Identification of a Characteristic Protein Expression Profile of Malignant Breast Epithelium Proteomics, 6: 1989 -2002
IF: 5,735
Singer CF and Hudelist G, Walter I, Rueckliniger E, Czerwenka K, Kubista E and Huber AV (2006) Tissue array-based expression of transglutaminase-2 in human breast and ovarian cancer Clin & Experiment Metastasis, 23(1):33-9
IF: 3,048
Gschwantler-Kaulich D, Fink-Retter A, Kubista E and Singer CF (2006) Prädiktive Onkologie. Gyn-Aktiv 1/06: 23-25
Langer S, Singer CF, Hudelist G, Dampier B, Kaserer K, Vinatzer U, Pehamberger H, Zielinski CC, Kubista E and Schreiber M Jun and Fos family protein expression in human breast cancer: Correlation of protein expression and clinicopathological parameters (2006) Europ J Gynecol Oncol, 27(4): 345-352
IF: 2,887
Singer CF, Hudelist G, Lamm W, Mueller R, Handl C, Kubista E and Czerwenka K (2006) Active (p)CrkL is overexpressed in human malignancies: potential role as a surrogate parameter for therapeutic tyrosine kinase inhibition, Oncology Reports 15(2): 353-359
IF: 1,572
Gschwantler-Kaulich D, Fink-Retter A, Kubista E and Singer CF (2006) Kosteneffektivität von Herceptin. Gyn-Aktiv 1/06: 20-21
Köstler WJ, Hudelist G, Rabitsch W, Czerwenka K, Müller R, Singer CF and Zielinski CC (2006) Insulin-like growth factor-I receptor (IGF-IR) expression does not predict for resistance to trastuzumab-based treatment in patients with Her-2/neu overexpressing metastatic breast cancer, J Canc Res Clin Oncol 132(1): 9-18
IF: 2,503
Hudelist G and Köstler WJ, Czerwenka K, Kubista E,Attems J, Müller R, Gschwantler-Kaulich D, Manavi M, Huber I, Hoschützky H, Zielinski CC and Singer CF (2006) Her-2/neu and EGFR tyrosine kinase activation predict the efficacy of trastuzumab-based therapy in patients with metastatic breast cancer. Int J Cancer, 118(5):1126-34
IF: 4,700
Hudelist G, Köstler WJ, Gschwantler-Kaulich D, Czerwenka K, Kubista E, Müller R, Helmy S, Manavi M, Zielinski CC and Singer CF (2006) Serum EGFR levels and efficacy of trastuzumab-based therapy in patients with metastatic breast cancer. Europ J Cancer, 42(2):186-92
IF: 3,706
Hudelist G, Keckstein J, Czerwenka K, Lass H, Walter I, Auer M, Wieser F, Wenzl R, Kubista E and Singer CF (2005) Estrogen receptor beta and matrix metalloproteinase-1 are co-expressed in uterine endometrium and endometriotic lesions of patients with endometriosis. Fertil Steril, 84 Suppl 2:1249-56
IF: 3,114
Hudelist G, Singer CF and Keckstein J (2005) Matrix-Metalloproteinasen (MMPs) und deren Bedeutung für die Menstruation und Endometriose. Zentralbl Gynakol 127: 318-322
Singer CF (2005) Herceptin – adjuvante Therapie des Mammakarzinoms. Ein neuer Standard. Gyn-Aktiv 5: 14-16
Hudelist G, Keckstein J, Czerwenka K, Lass H, Walter I, Auer M, Wieser F, Wenzl R, Kubista E, and Singer CF (2005) Estrogen receptor alpha and matrix metalloproteinase 1 are co-expressed in uterine endoemtrium and endometriotic lesions of patients with endometriosis. Fertil Steril, 84 Suppl 2:1249-56
IF: 3,114
Gschwantler-Kaulich D, Fink A, Kubista E and Singer CF (2005) Predictive Oncology. Senologie, 4/2005: 8-9
Hudelist G, Singer CF, Kubista E, and Czerwenka K (2005) Use of high-throughput arrays for profiling differentially expressed proteins in normal and malignant tissues. Anticancer Drugs 16(7): 683-689
IF: 1,907
Gschwantler-Kaulich D, Hudelist G, Koestler WJ, Czerwenka K, Mueller R, Ruecklinger E, Kubista E and Singer CF (2005) EGFR activity in HER-2 over-expressing metastatic breast cancer: evidence for simultaneous phosphorylation of Her-2/neu and EGFR. Oncology Reports 14(2): 305-11
IF: 1,572
Hudelist G, Lass H, Keckstein J, Walter I, Wieser F, Wenzl F, Mueller R, Czerwenka K, Kubista E, and Singer CF (2005) Interleukin 1 alpha (IL1a) and tissue-lytic matrix metalloproteinase-1 (MMP-1) are elevated in ectopic endometrium of patients with endometriosis. Human Reproduction 20(6): 1695-701
IF: 3,669
Singer CF and Kubista E (2005) Prädiktive Onkologie. Speculum – Zeitschrift für Gynäkologie und Frauenheilkunde 23 (1): 9-11
Koestler WJ, Brodowicz T, Hudelist G, Rudas M, Horvat R, Steger GG, Singer CF, Attems J, Rabitsch W, Fakhrai N, Elandt K, Wiltschke C, Hejna M, and Zielinski CC (2005) The Efficacy of Trastuzumab in Her-2/neu Overexpressing Metastatic Breast Cancer is Independent from p53 Status. J Cancer Research and Clinical Oncology 131(7): 420-428
IF: 2,366
Singer CF (2005) Herzeptintherapie – Neue Indikationen? GYN-AKTIV, 1:15-18
Koestler W, Steger GG, Krainer M, Kornek G, Locker G, Brodowicz T, Marosi C, Singer CF, Hudelist G, Rabitsch W, Wiltschke C, and Zielinski CC (2005) Single Agent Trastuzumab versus Trastuzumab plus Cytotoxic Chemotherapy in Metastatic Breast Cancer: A single Institution Experience. Anticancer Drugs 16(2):185-90
IF: 1,907
Hudelist G, Gellen J, Singer CF, Ruecklinger E, Czerwenka K, Kandolf O, and Keckstein J (2005) Occurrence and risk factors predicting severe perineal trauma during childbirth in a referral hospital: role of assisted vaginal delivery. American Journal of Obstetrics and Gynecology 193:875-881
IF : 3,083
Huber A, Hudelist G, Czerwenka K, Husslein P, Kubista E, and Singer CF (2005) Cervical effacement is associated with a characteristic gene expression profile in the cDNA Array analysis of cervical biopsies American Journal of Obstetrics and Gynecology, 105(1): 91-98
IF: 3,083
Hudelist G, Czerwenka K, Singer CF, Pischinger K, Kubista E, and Manavi M (2005) Cytobrush-collected malignant cervical epithelial cells display a cancer-specific gene expression pattern in cDNA Array analysis. Cancer Genetics and Cytogenetics 158,1:35-42
IF: 1,640
Huber AV, Huber CJ, Kolbus A, Martin Imhof M, Nagele F, Loizou D, Kaufmann U, and Singer CF (2004) Effects of Systemic HCG Treatment on Patients with Endometriosis: a New Perspective for a Painful Disease. Wien Klin Wochenschr 116 (24): 839-843
IF: 0,774
Singer CF, Hudelist G, Lamm W, Mueller R, Czerwenka K, and Kubista E (2004) Expression of membrane-associated tyrosin kinases in human malignancies as potential targets for kinase-specific inhibitors. Endocrine Related Cancer 11(4): 861-869
IF: 8,894
Hudelist G, Singer CF, Kubista E, Mueller R, and Czerwenka K (2004) Nanobacteria - a possible cause for the development of psammoma bodies in ovarian cancer. Histopathology 45: 633-637
IF: 2,952
Hudelist G, Pacher M, Singer CF, Holper T, Kubista E, Schreiber M, Manavi M, Bilban M, and Czerwenka K (2004) Use of high-throughput protein arrays for profiling of differentially expressed proteins in normal and malignant breast tissue. Breast Cancer Research and Treatment, 86(3): 283-293
IF: 2,964
Grunt TW, Singer CF, and Solca F (2004) Disease Models of Cancer: HER2 And Breast Cancer, Drug Discovery Today: Disease Models 1 (1): 17-23
IF: 4,934
Hudelist G, Koestler W, Czerwenka K, Kubista E, and Singer CF (2004) Predicting the clinical course of breast cancer patients undergoing trastuzumab-based therapy: an outlook, Methods Find Exp Clin Pharmacol. 26 (3): 201-210
IF: 0,613
Koestler WJ, Steger GG, Soleiman A, Schwab B, Singer CF, Tomek S, Brodowicz T, Krainer M, Wiltschke C, Horvat R, Jakesz R, and Zielinski CC (2004) Monitoring of Serum Her-2/neu Predicts Histopathologic Response to Neoadjuvant Trastuzumab-based Therapy for Breast Cancer, Anticancer Research, 24: 1127-1130
IF: 1,347
Singer CF, Mogg M, Koestler W, Marton E, Pacher M, Kubista E, and Schreiber M (2004) IGF-1 and IGF-2 Serum Concentrations in Patients with Benign and Malignant Breast Lesions: Free IGF-2 is Correlated with Breast Cancer Size. Clinical Cancer Res 10: 4003-4009
IF: 6,511
Hudelist G, Manavi M, Pischinger KI, Watkins-Riedel T, Singer CF, Kubista E, and Czerwenka KF (2004) Physical state and expression of HPV DNA in benign and dysplastic cervical tissue: different levels of viral integration are correlated with lesion grade. Gynecol Oncol 92(3): 873-880
IF: 2,341
Koestler WB, Schwab B, Singer CF, Neumann R, Rücklinger E, Marton E, Brodowicz T, Tomek S, Hejna M, Steger G, Krainer M, Wiltschke C, and Zielinski CC (2004) Monitoring of Serum Her-2/neu predicts Response and Progression-free Survival to Trastuzumab in Patients with Metastatic Breast Cancer, Clinical Cancer Res 10: 1618-1624
IF: 6,511
Asseryanis, E, Ruecklinger, E, Hellan, M, Kubista, E and Singer CF (2004) Breast Cancer Size is correlated with body mass index and androgen serum levels. Gynecological Endocrinology 18 (1): 29-36
IF: 0,870
Singer CF, Kronsteiner N, Hudelist G., Marton E, Walter I, Kubista M, Czerwenka, K, Schreiber M, Seifert M, and Kubista E (2003) IL-1 system and sex steroid receptor expression in human breast cancer: IL-1alpha protein secretion is correlated with malignant phenotype, Clinical Cancer Res 9: 4877-4883
IF: 5,623
Hudelist G, Kostler WJ, Attems J, Czerwenka K, Muller R, Manavi M, Steger GG, Kubista E, Zielinski CC, and Singer CF (2003) Her-2/neu-triggered intracellular tyrosine kinase activation: in vivo relevance of ligand-independent activation mechanisms and impact upon the efficacy of trastuzumab-based treatment. Br J Cancer 89: 983-991
IF: 3,639
Hudelist G, Singer CF, Manavi M, Pischinger K, Kubista E, Czerwenka K (2003) Co-expression of ErbB-family members in human breast cancer: Her-2/neu is the preferred dimerization candidate in nodal-positive tumors. Breast Cancer Res Treat 80: 353-361
IF: 3,132
Koestler WJ, Amann G, Grunt TW, Singer CF, Schneider SM, Brodowicz T, Tomek S and Zielinski CC. (2003) Recurrent Malignant Triton Tumour - First report on a long time survivor, Oncology Reports 10(3): 533-535
IF: 1,171
Hudelist G, Czerwenka K, Kubista E, Marton E, Pischinger K, and Singer CF (2003) Expression of Sex Steroid Receptors and their Co-factors in Normal and Malignant Breast Tissue: AIB1 Is a Carcinoma-Specific Co-Activator, Breast Cancer Research and Treatment 78 (2): 193-204
IF: 3,132
Singer CF, Hudelist G, Schreiber M, and Kubista E (2003) Pharmacological modulation of IGF concentrations as a therapeutical approach in controlling the size of malignant breast tumors, Drugs Today 39 (2): 115-125
IF: 0,258
Jelincic D, Hudelist G, Singer CF, Bauer M, Horn LC, Bilek K, and Czerwenka K (2003) Klinisches und pathologisches Profil gestationsbedingter Trophoblast-tumoren. Wiener Klinische Wochenzeitschrift 115 (1-2): 29-35
IF: 0,591
Wieser F, Schneeberger C, Hudelist G, Singer C, Kurz C, Nagele F, Gruber C, Huber JC and Tschugguel W. (2002) Endometrial nuclear receptor co-factors SRC-1 and N-CoR are increased in Human Endometrium during menstruation, Molecular Human Reproduction, 8 (7): 644-650
IF: 2,751
Singer CF, Kronsteiner N, Marton E, Walter I, Kubista M, Czerwenka K, Schreiber M, Tschugguel W, Wieser F, Kubista E (2002) IL-1alpha gene expression in human endometrial cancer is independent of ovarian steroid receptor expression. Eur J Cancer 38(Suppl 6): 76-77
IF : 3,562
Hirtenlehner K, Pec M, Kubista E, and Singer CF (2002) Extracellular Matrix Proteins influence phenotype and cytokine expression of human breast cancer cell lines, Eur Cytokine Netw 13: 234-240
IF: 1,677
Hirtenlehner K, Pec M, Kubista E, and Singer CF (2002) Influence of stroma-derived growth factors on the cytokine expression pattern of human breast cancer cell lines Archives of Gynecology and Obstetrics 266 (2): 108-13
IF: 0,666
Singer CF, Kronsteiner N, Marton E, Walter I, Kubista M, Czerwenka K, Schreiber M, Tschugguel W, Wieser F, and Kubista E (2002) IL-1 system and sex steroid receptor gene expression in human endometrial cancer, Gynecol Oncol 85 (3): 423-430
IF: 2,200
Singer CF, Kronsteiner N, Marton E, Kubista M, Cullen, KJ, Hirtenlehner K, Seifert M, and Kubista E (2002) MMP-2 and MMP-9 expression in breast cancer-derived human fibroblasts is differentially regulated by stromal-epithelial interactions, Breast Cancer Res. and Treat. 72 (1): 69-77
IF: 2,866
Henriet P, Cornet P, Lemoine P, Singer CF, Courtoy PJ, Eeckhout Y, and Marbaix E (2002) Circulating sex hormones and endometrial matrix metalloproteinases (MMPs), Annals N.Y. Acad. Sci. 955: 119-139
IF: 1,593
Singer CF, Kubista E, Garmroudi F, and Cullen KJ (2000) Local feedback mechanisms in human breast cancer. Breast Cancer Res. and Treat. 63: 95-104
IF: 2,889
Singer CF, Marbaix E, Kokorine I, Lemoine P, Donnez J, Eeckhout Y, and Courtoy PJ (2000) The Matrix metalloproteinase-1 (MMP-1) expression in the human endometrium is inversely regulated by interleukin-1alpha and sex steroids. Cescá Gynecologie 65: 211-215
Obwegeser R, Berghammer P, Rodrigues M, Granegger S, Hohlagschwandtner M, Kucera H, Singer C, Berger A, Kubista E, and Sinzinger H (1999) A head-to-head comparison between 99M-Tc-Tetrofosmin and 99M-Tc-MIBI scintigraphy to evaluate suspicious breast lesions. Eur. J. Nucl. Med., 26, 1553-1559
IF: 3,239
Singer CF, Marbaix E, Lemoine P, Eeckhout Y, and Courtoy PJ (1999) Interleukin-1 receptor-ligand interactions modulate interstitial collagenase-1 production by human endometrial fibroblasts. Mol. Hum. Reprod., 5, 240-245 [nbsp
Lecturing and scientific work
Professor of OB/GYN at Medical University of Vienna, Austria, research interests in breast cancer and menopausal medicine
